#China #Innovation #Hangzhou #medical technology #Zylox-Tonbridge

Zylox-Tonbridge Reports Strong 2025 Interim Results

Zylox-Tonbridge Medical Technology Co., Ltd. has made headlines with the release of its interim results for the first half of 2025, demonstrating impressive financial performance marked by strong revenue growth and substantial net profit increase. The results published on August 20, 2025, reveal a remarkable year-over-year revenue hike of 31.7%, bringing the total to RMB 482 million. In addition, net profit soared to over RMB 121 million, an extraordinary rise of 76.0%, resulting in a net profit margin of 25.1%.

Solid Performance in Key Business Areas

In this half-year report, Zylox-Tonbridge highlighted its success in the core areas of neurovascular and peripheral vascular interventions. Revenue from neurovascular products alone reached RMB 304 million, reflecting a 25.0% increase year-over-year. Meanwhile, peripheral vascular product revenue experienced a significant jump of 46.2%, climbing to RMB 176 million. This robust performance can be attributed to the Company's ongoing commitment to lean operations, which has led to a 7 percentage point reduction in combined research, development, selling, and administrative expenses as a percentage of revenue compared to the previous year.

Internationally, Zylox-Tonbridge also reported strong business growth, recording revenue of RMB 15.72 million from overseas operations. By June 30, the Company had launched 22 products across 27 countries and regions, and has over 31 products currently in the registration process across 23 markets. Its global network now spans 52 countries, facilitated by partnerships with over 60 local distributors. This expansion of international business reflects Zylox-Tonbridge's strategy to boost revenue and capture new markets as an emerging growth driver.

Mature Product Portfolio Fuels Growth

Zylox-Tonbridge's robust performance is supported by a diverse and high-quality product portfolio, coupled with an effective sales team. The Company successfully renewed contracts for several Value-Based Purchasing (VBP) selected products under a traditionally stable procurement environment, which has enabled further market penetration and increased market share. Key products such as the SilverSnake® Intermediate Catheter Series, Kylin™ Flow Diverter, and UltraFree® Drug-Coated PTA Balloon Catheter have reported strong sales growth, showcasing increased market penetration.

As of this report, Zylox-Tonbridge's products have been utilized in over 1 million procedures across more than 3,000 hospitals, emphasizing the Company's commitment to delivering high-quality and affordable medical solutions to patients globally.

Zylox-Tonbridge remains focused not only on scaling up its mature products but also on innovating to address unmet clinical needs. The first half of 2025 witnessed regulatory approvals for the ZYLOX Eagle® Aspiration System and the TONBRIDGE Shunfeng™ Balloon Vascular Closure Device, signifying a commitment to enhancing its product lineup. The Company anticipates additional approvals for various innovative devices in the latter half of the year, including a large-lumen thrombus aspiration catheter, self-expandable intracranial stent, and an OCT-guided peripheral atherectomy catheter series.

Among the noteworthy contributions to the product pipeline is the Mammoth Peripheral Large Lumen Thrombus Aspiration Catheter, noted for its effective design aimed at treating deep vein thrombosis. Additionally, in the neurovascular sphere, the development of a self-expanding aneurysm embolization device is set to tackle the complexities of treating wide-neck bifurcation aneurysms.

Continued Global Expansion

In line with its growth strategy, Zylox-Tonbridge has significantly increased its investment in international research and development, as well as regulatory registration processes, underpinning its rapid global expansion. Its products are now making strides in seven of the world's ten largest medical device markets, including crucial European markets such as France, Germany, and Italy while also thriving in emerging markets like Brazil, India, and South Africa.

The ZYLOX Unicorn™ Vascular Closure System, which received regulatory approval in Indonesia, represents the Company’s footprint expansion into Southeast Asia. The approval of the ZYLOX Phoenix™ Peripheral Fibered Detachable Coil Occlusion System in Ecuador also enhances the Company’s presence in South America. To boost brand recognition in Europe, Zylox-Tonbridge has participated in major conferences like LINC 2025 and LINNC PARIS 2025, promoting its commitment to product quality and market leadership.

Zylox-Tonbridge persistently drives forward under the vision of